Clinical trials: Amyotrophic Lateral Sclerosis ALS
Amyotrophic Lateral Sclerosis (ALS)
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
The purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in patients with ALS who had completed the double-blind placebo-controlled study of tirasemtiv in ALS (CY 4031).
- Trial name
- VIGOR-ALS (NCT02936635)
- Testing
- tirasemtiv
- Where
- 67 sites in United States, Belgium and 9 more
- Volunteers
- 280 people
- Sponsor
- Cytokinetics
Amyotrophic Lateral Sclerosis
3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Phase 2 open label trial to investigate the safety and potentially efficacy of 3K3A-APC in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT05039268
- Testing
- 3K3A-APC Protein
- Where
- Australia
- Volunteers
- 16 people
- Sponsor
- Macquarie University, Australia
ALS
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
The purpose of this research study is to evaluate the safety and effectiveness of Ranolazine, and how well it is tolerated in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT03472950
- Testing
- Ranolazine 500 MG, Ranolazine 1000 MG
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Kansas Medical Center
Amyotrophic Lateral Sclerosis
Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis
The purpose of this study was to evaluate the safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis as compared to Placebo.
- Trial name
- REViVALS-1A (NCT04632225)
- Testing
- Engensis
- Where
- 5 sites in United States, South Korea
- Volunteers
- 18 people
- Sponsor
- Helixmith Co., Ltd.
Amyotrophic Lateral Sclerosis, Muscle Cramp
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
The primary objective of the study is to demonstrate the safety and potential efficacy of TJ-68 for improving muscle cramps in participants with ALS based on a two-site, randomized, placebo-controlled double-blind multi-period…
- Trial name
- NCT04998305
- Testing
- TJ-68
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Hiroshi Mitsumoto
Amyotrophic Lateral Sclerosis (ALS)
Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis
The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores…
- Trial name
- NCT01492686
- Testing
- MCI-186, MCI-186 in open label phase
- Where
- Japan
- Volunteers
- 137 people
- Sponsor
- Shionogi
ALS, Amyotrophic Lateral Sclerosis
A Trial of Tocilizumab in ALS Subjects
This research study is being done to find out if tocilizumab, also known as Actemra™, can help with Amyotrophic Lateral Sclerosis (ALS).
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Motor Neuron Disease
- Trial name
- TCZALS-001 (NCT02469896)
- Testing
- Tocilizumab
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Barrow Neurological Institute
Amyotrophic Lateral Sclerosis
HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Background: Some people with Amyotrophic Lateral Sclerosis (ALS) have a high level of the virus HERV-K in their blood. Researchers do not think this virus causes ALS.
- Trial name
- NCT02437110
- Testing
- Darunavir, Ritonavir, Dolutegravir
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis
A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis
- Trial name
- ADOREXT (NCT05866926)
- Testing
- FAB122
- Where
- Spain
- Volunteers
- 201 people
- Sponsor
- Ferrer Internacional S.A.
Amyotrophic Lateral Sclerosis (ALS)
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
This is a multi-center, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of autologous (self) transplantation of Neurotrophic factors-secreting Mesenchymal Stromal Cells (MSC-NTF, NurOwn™) in…
- Trial name
- NurOwn (NCT02017912)
- Testing
- Nurown MSC-NTF cells
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Brainstorm-Cell Therapeutics
Amyotrophic Lateral Sclerosis
An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
The primary objectives of Parts A and B of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of tofersen in adults with ALS and a documented superoxide dismutase 1 (SOD1) mutation.
- Trial name
- VALOR (Part C) (NCT02623699)
- Testing
- Tofersen
- Where
- 40 sites in United States, Australia and 10 more
- Volunteers
- 176 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Gilenya in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine whether Gilenya, also known as fingolimod, is safe and tolerable in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01786174
- Testing
- Gilenya
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial
The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients.
- Trial name
- NCT00035815
- Testing
- Insulin like growth factor, type 1
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 330 people
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis
HEALEY ALS Platform Trial - Regimen A Zilucoplan
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
- Trial name
- NCT04436497
- Testing
- Zilucoplan
- Where
- United States
- Volunteers
- 162 people
- Sponsor
- Merit E. Cudkowicz, MD
Sporadic Amyotrophic Lateral Sclerosis
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)
The purpose of this research is to find out if mexiletine is safe and effective in people with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- MX-ALS-001 (NCT01849770)
- Testing
- Mexiletine
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- University of Washington
Amyotrophic Lateral Sclerosis, ALS
An Efficacy and Safety Study of Ravulizumab in ALS Participants
The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.
- Trial name
- NCT04248465
- Testing
- Ravulizumab
- Where
- 95 sites in United States, Australia and 15 more
- Volunteers
- 382 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis ALS
ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments
GenieUs developed an analysis platform that will be tested to separate study participants with ALS into four categories based on blood work.
- Trial name
- NCT06429059
- Testing
- Astaxanthin, Protandim, Melatonin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Duke University
Amyotrophic Lateral Sclerosis
Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis
This is a pilot, phase 2, prospective, open-label, single-arm study to evaluate disease progression, forced vital capacity, and the safety and tolerability of plasma exchange (PE) using Albutein® 5% in participants with…
- Trial name
- NCT02872142
- Testing
- Albutein 5%, Plasma Exchange
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Grifols Therapeutics LLC
Amyotrophic Lateral Sclerosis
Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)
This is a multi-center, 20-week study of inosine treatment. Study Objectives and Endpoints The primary objective of the study is to determine the safety and tolerability of oral administration of inosine (administered daily)…
- Trial name
- SURE-ALS2 (NCT03168711)
- Testing
- Inosine
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
Cervical Electrical Stimulation for ALS
Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). ALS causes degeneration of motor neurons in both the brain and the spinal cord.
- Trial name
- NCT03411863
- Testing
- CES at rest, CES plus active hand or wrist movements
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development